The Pharma Data

Mirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading biopharmaceutical firm specializing in the discovery, acquisition, development, and distribution of innovative therapies for rare and orphan diseases, has revealed its participation in forthcoming investor conferences as follows: For webcast links and additional…

Read MoreMirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences

Oragenics, Inc. Readies Phase II Clinical Trials for Concussion Treatment Drug

Oragenics, Inc. (NYSE American: OGEN), a company dedicated to developing innovative intranasal pharmaceuticals for neurological disorders, has revealed its readiness to embark on the final stages of GMP manufacturing and formulation for its drug candidate, ahead of the anticipated Phase…

Read MoreOragenics, Inc. Readies Phase II Clinical Trials for Concussion Treatment Drug

Alnylam’s KARDIA-2 Study Shows Zilebesiran Adds Significant Blood Pressure Reduction

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNAi therapeutics, has announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for treating hypertension. The study met its primary endpoint, demonstrating…

Read MoreAlnylam’s KARDIA-2 Study Shows Zilebesiran Adds Significant Blood Pressure Reduction

Argonaut Manufacturing Services Boosts Aseptic Pharma Filling with $45M Investment

Argonaut Manufacturing Services Secures $45M Funding for Expanded Pharma Fill / Finish Facility Argonaut Manufacturing Services, a prominent contract development and manufacturing organization in the biopharma and life sciences sectors, has finalized a $45 million financing deal to bolster its…

Read MoreArgonaut Manufacturing Services Boosts Aseptic Pharma Filling with $45M Investment

2032 Myocardial Infarction Treatment Insights: FARXIGA Forecast – ResearchAndMarkets.com

ResearchAndMarkets.com is pleased to announce the addition of the “FARXIGA Market Size, Forecast, and Emerging Insight – 2032” report to its offerings. This comprehensive report delves into the impact and projected growth of FARXIGA in the treatment landscape of myocardial…

Read More2032 Myocardial Infarction Treatment Insights: FARXIGA Forecast – ResearchAndMarkets.com

United Therapeutics Corporation Scheduled to Participate in the Leerink Partners Global Biopharma Conference 2024

United Therapeutics Corporation (Nasdaq: UTHR), a leading public benefit corporation, has disclosed that Patrick Poisson, Executive Vice President of Technical Operations, will participate in a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.…

Read MoreUnited Therapeutics Corporation Scheduled to Participate in the Leerink Partners Global Biopharma Conference 2024

Successful Large-Scale GMP Manufacturing of MOv18 IgE Antibody for Ovarian Cancer by Epsilogen and Lonza

Epsilogen and Lonza Achieve Breakthrough in Manufacturing IgE Antibody for Ovarian Cancer Treatment Epsilogen, a leader in developing IgE antibodies for cancer therapy, and Lonza, a global partner in pharmaceutical manufacturing, have announced the successful completion of Good Manufacturing Practice…

Read MoreSuccessful Large-Scale GMP Manufacturing of MOv18 IgE Antibody for Ovarian Cancer by Epsilogen and Lonza